ArticleBiomedical engineering online2026
LncRNA RNF144A-AS1 increases P300-mediated H4K5 acetylation of PDE4 to promote keloid fibrosis.
Article in Biomedical engineering online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A panoramic analysis of keloid pathogenesis: multidimensional network regulation of genetics-immunity-metabolism-mechanical force.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundKeloid fibrosis is characterized by aberrant fibroblast activation and excessive collagen accumulation following cutaneous injury. This study investigates the mechanism by which LncRNA RNF144A-AS1 promotes keloid fibrosis by mediating H4K5 acetylation, providing potential targets for developing novel therapeutic interventions.
methodsKeloid fibroblasts were transfected with si-RNF144A-AS1, followed by detection of RNF144A-AS1, HUR, P300, and PDE4 expression. The levels of TNF-α, TGF-β1, and IL-1β were measured by ELISA. The expression of α-SMA, COL1A1, HUR, P300, and PDE4 was assessed by western blot. The binding between RNF144A-AS1 and HUR was validated using RIP and RNA pull-down assays. Actinomycin D treatment was used to assess P300 mRNA stability. The enrichment of P300 and H4K5ac on the PDE4 promoter was detected by Ch-IP. Combined experiments were used to verify the role of RNF144A-AS1 in keloid fibrosis via the P300/PDE4 axis. Bleomycin sulfate-induced keloid mouse models were established. After silencing RNF144A-AS1 in mice, the skin tissue changes, dermal thickness, and collagen deposition were evaluated. α-SMA and TGF-β1 expression was detected by IHC.
resultsRNF144A-AS1 was highly expressed in keloid fibrosis cell models. RNF144A-AS1 downregulation reduced cell viability and decreased the expression of TGF-β1, TNF-α, IL-1β, α-SMA, and COL1A1. RNF144A-AS1 bound to HUR to promote P300 expression. P300 upregulated histone H4K5 acetylation on the PDE4 promoter, enhancing PDE4 expression. Overexpression of P300 or PDE4 partially reversed the inhibitory effects of RNF144A-AS1 knockdown on keloid fibrosis. Silencing RNF144A-AS1 suppressed keloid fibrosis in vivo.
conclusionsRNF144A-AS1 drives keloid fibrosis through P300-mediated H4K5 acetylation of PDE4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.